Human umbilical cord-derived mesenchymal stem cell therapy (Beilai)

人脐带间充质干细胞（贝来生物）

Report date: 2026/04/20 20:01:59

Base Information

Drug NameHuman umbilical cord-derived mesenchymal stem cell therapy (Beilai)
Drug Alias NameBC-U001
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAlzheimer DiseaseIdiopathic Pulmonary FibrosisAcute-On-Chronic Liver Failure +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Beilai Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Beilai Biotechnology Co LtdBeijing Belai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAlzheimer DiseaseIdiopathic Pulmonary FibrosisAcute-On-Chronic Liver Failure +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A